Cargando…
Post-approval studies with the CFTR modulators Elexacaftor-Tezacaftor—Ivacaftor
Triple combination therapy with the CFTR modulators elexacaftor (ELX), tezacaftor (TEZ) and ivacaftor (IVA) has been qualified as a game changer in cystic fibrosis (CF). We provide an overview of the body of literature on ELX/TEZ/IVA published between November 2019 and February 2023 after approval b...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10072268/ https://www.ncbi.nlm.nih.gov/pubmed/37025483 http://dx.doi.org/10.3389/fphar.2023.1158207 |